2 results
Approved WMOCompleted
Part 1: To assess the safety and effectiveness of subcutaneous golimumab 50 mg (SC-GLM50), administered by autoinjection once monthly during 6 months, when combined with different DMARD regimens used in daily rheumatology. Part 2: In subjects who…
Approved WMORecruiting
The primary objective of this study is to determine the competence of a magnetic marker as a technique to localise non-palpable breast cancer, measured through retrieval rate using only the magnetic probe. The secondary objectives of this study are…